Vanda Pharmaceuticals Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Vanda Pharmaceuticals Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000739). The exact share count and percentage were not specified in the headline disclosure. The filing signals that State Street, a major institutional asset manager, has crossed the 5% beneficial ownership threshold that triggers passive-investor reporting requirements. Investors will watch for the full 13G details, including the precise share total and whether the position reflects index-related or discretionary holdings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Vanda Pharmaceuticals Inc., State Street Corp